How Rapid and Molecular Diagnostics Are Shaping the Brucellosis Test Kits Market According to a newly published market research report by 24LifeSciences, global brucellosis test kits market is valued at USD 315.7 million in 2026 and is projected to reach USD 458.6 million by 2034, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period. Brucellosis test kits are in-vitro diagnostic (IVD) tools designed for the serological detection of antibodies against Brucella bacteria, a critical component in diagnosing both human and animal brucellosis. These kits play an essential role in managing this zoonotic disease, which causes significant economic losses in livestock production and poses serious public health risks. The most common formats include Brucella IgG, IgM, and IgA ELISA kits, along with traditional methods like rose bengal plate tests (RBPT) and advanced fluorescence polarization assays (FPA). Their accuracy and reliability make them indispensable for veterinary diagnostics, food safety programs, and human healthcare systems worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9628/brucellosis-test-kits-market

Top 10 Players Shaping the Global Hepatitis E Diagnostic Tests Market (2026–2034) According to a newly published market research report by 24LifeSciences, global Hepatitis E Diagnostic Tests market is valued at USD 40.1 million in 2026 and is projected to reach USD 47.1 million by 2034, growing at a compound annual growth rate (CAGR) of 2.4% during the forecast period. Hepatitis E diagnostic tests are critical medical tools designed to detect the presence of the Hepatitis E Virus (HEV), an RNA virus responsible for acute liver inflammation. These tests are indispensable for confirming infection, particularly during outbreaks and for high-risk populations such as pregnant women, immunocompromised individuals, and patients with pre-existing liver conditions. The primary diagnostic methodologies include Enzyme-Linked Immunosorbent Assay (ELISA) kits, which identify IgM and IgG antibodies, and advanced molecular techniques like Reverse Transcription-Polymerase Chain Reaction (RT-PCR) tests that detect viral RNA directly, offering high specificity and sensitivity. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9474/hepatitis-e-diagnostic-tests-market

How Targeted Cancer Therapies Are Driving the MUC1 Antibody Market Growth According to a newly published market research report by 24LifeSciences, global MUC1 Antibody market is valued at USD 450 million in 2026 and is projected to reach USD 1,066 million by 2034, growing at a compound annual growth rate (CAGR) of 13.4% during the forecast period. MUC1 Antibodies are specialized immunoglobulins targeting Mucin 1, a transmembrane glycoprotein overexpressed in multiple carcinomas including breast, pancreatic, and ovarian cancers. These antibodies enable detection through techniques such as flow cytometry, ELISA, and immunohistochemistry, playing critical roles in cancer research, diagnostics, and therapeutic development. With breast cancer alone accounting for 2.3 million new cases globally in 2022 according to WHO data, the established importance of MUC1 as a biomarker continues to drive market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3018/muc-antibody-market-market